Cargando…

Correction: High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck

Detalles Bibliográficos
Autores principales:	Shames, David S., Carbon, Juliet, Walter, Kim, Jubb, Adrian M., Kozlowski, Cleopatra, Januario, Tom, Do, An, Fu, Ling, Xiao, Yuanyuan, Raja, Rajiv, Jiang, Brittany, Malekafzali, Ashi, Stern, Howard, Settleman, Jeff, Wilson, Timothy R., Hampton, Garret M., Yauch, Robert L., Pirzkall, Andrea, Amler, Lukas C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731370/ http://dx.doi.org/10.1371/annotation/63f57c72-c869-4ef5-94d1-3cbd6c2e3678

Ejemplares similares

High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck
por: Shames, David S., et al.
Publicado: (2013)

A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer
por: Mota, Jose Mauricio, et al.
Publicado: (2017)

Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin
por: Buta, Corina, et al.
Publicado: (2016)

Predicting response to HER2 kinase inhibition
por: Settleman, Jeff
Publicado: (2014)

Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2004)

Erratum to: Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin
por: Buta, Corina, et al.
Publicado: (2016)

ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3
por: Ebbing, Eva A., et al.
Publicado: (2016)

Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells
por: Kang, Jeffrey C, et al.
Publicado: (2014)

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells
por: Kawakami, Hisato, et al.
Publicado: (2014)

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models
por: Xia, Wenle, et al.
Publicado: (2013)

A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance
por: Al-Akhrass, Hussein, et al.
Publicado: (2021)

H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation via heregulin production and activation of HER3
por: Chakrabarty, Anindita, et al.
Publicado: (2010)

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1
por: Nonagase, Yoshikane, et al.
Publicado: (2016)

Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines
por: Momeny, Majid, et al.
Publicado: (2015)

The in vitro influences of epidermal growth factor and heregulin-β1 on the efficacy of trastuzumab used in Her-2 positive breast adenocarcinoma
por: Hurrell, Tracey, et al.
Publicado: (2013)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells
por: Kim, Sangmin, et al.
Publicado: (2012)

γ-Heregulin has no biological significance in primary breast cancer
por: Sánchez-Valdivieso, E A, et al.
Publicado: (2002)

Heregulin, a new regulator of telomere length in human cells
por: Menendez, Javier A., et al.
Publicado: (2015)

Heregulin Activity Assays for Residual Testing of Cell Therapy Products
por: Monje, Paula V., et al.
Publicado: (2021)

Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer
por: Mitsui, Keigo, et al.
Publicado: (2014)

Heregulin, a new interactor of the telosome/shelterin complex in human telomeres
por: Menendez, Javier A., et al.
Publicado: (2015)

Androgen receptor transcriptional activity is required for heregulin-1β–mediated nuclear localization of the HER3/ErbB3 receptor tyrosine kinase
por: Jathal, Maitreyee K., et al.
Publicado: (2023)

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI
por: Yonesaka, Kimio, et al.
Publicado: (2019)

Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer
por: Papadimitropoulou, Adriana, et al.
Publicado: (2020)

Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
por: Huebner, Hanna, et al.
Publicado: (2020)

Optimizing the treatment of BRAF mutant melanoma
por: Settleman, Jeff
Publicado: (2014)

Suppression of Heregulin-β1/HER2-Modulated Invasive and Aggressive Phenotype of Breast Carcinoma by Pterostilbene via Inhibition of Matrix Metalloproteinase-9, p38 Kinase Cascade and Akt Activation
por: Pan, Min-Hsiung, et al.
Publicado: (2011)

Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by heregulin
por: Yoo, J-Y, et al.
Publicado: (2000)

Scattering of MCF7 Cells by Heregulin ß-1 Depends on the MEK and p38 MAP Kinase Pathway
por: Okoshi, Rintaro, et al.
Publicado: (2013)

Discovering Tumor Suppressor Genes Through Genome-Wide Copy Number Analysis
por: Rothenberg, S. Michael, et al.
Publicado: (2010)

Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?
por: Benes, Cyril, et al.
Publicado: (2009)

Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells
por: Hutcheson, Iain R, et al.
Publicado: (2007)

Overexpression of CD44 in acquired tamoxifen-resistant breast cancer cells augments their migratory response to heregulin beta 1
por: Hiscox, S, et al.
Publicado: (2008)

ErbB3 Ligand Heregulin1 Is a Major Mitogenic Factor for Uncontrolled Lung Cancer Cell Proliferation()()
por: Ma, Shiqi, et al.
Publicado: (2019)

Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2020)

Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancer
por: Steele, Thomas M., et al.
Publicado: (2023)

An Automated Method to Quantify Microglia Morphology and Application to Monitor Activation State Longitudinally In Vivo
por: Kozlowski, Cleopatra, et al.
Publicado: (2012)

Integrative Genome-Wide Expression Analysis Bears Evidence of Estrogen Receptor-Independent Transcription in Heregulin-Stimulated MCF-7 Cells
por: Nagashima, Takeshi, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_4ch8eisdgt4nebo2a3mgp58dp2